Try our Advanced Search for more refined results

Expert Analysis

Examining FDA Reauthorization Act Add-On Provisions

By John Manthei, Elizabeth Richards, Morgan Rettig and Nathan Beaton (August 25, 2017, 3:57 PM EDT) -- On Aug. 18, 2017, President Donald Trump signed into law the Food and Drug Administration Reauthorization Act (FDARA), which previously passed in the Senate by a vote of 94-1,[1] following passage in the House by unanimous consent.[2] The enactment of the FDARA represents the culmination of years of negotiations between the U.S. Food and Drug Administration, industry, consumer groups and other stakeholders....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!